IQVIA (NYSE:IQV) Lifted to “Buy” at StockNews.com

IQVIA (NYSE:IQV) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Wednesday.

Several other equities analysts also recently weighed in on the stock. Royal Bank of Canada assumed coverage on shares of IQVIA in a report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price target on the stock. Redburn Atlantic initiated coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 target price for the company. Argus upgraded shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Robert W. Baird increased their price target on IQVIA from $251.00 to $256.00 and gave the stock a “neutral” rating in a research report on Friday, September 20th. Finally, JPMorgan Chase & Co. decreased their price objective on IQVIA from $288.00 to $279.00 and set an “overweight” rating for the company in a report on Wednesday, October 23rd. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $267.27.

IQVIA Stock Down 0.6 %

IQVIA stock opened at $216.34 on Wednesday. IQVIA has a fifty-two week low of $167.42 and a fifty-two week high of $261.73. The company has a market cap of $39.44 billion, a PE ratio of 28.10, a PEG ratio of 2.09 and a beta of 1.49. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The business’s 50-day simple moving average is $236.50 and its two-hundred day simple moving average is $230.16.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of IQVIA

Several large investors have recently made changes to their positions in the company. 1832 Asset Management L.P. lifted its holdings in IQVIA by 472.3% in the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after purchasing an additional 376,595 shares in the last quarter. Renaissance Technologies LLC acquired a new position in IQVIA during the second quarter worth about $70,610,000. Impax Asset Management Group plc grew its stake in IQVIA by 19.3% during the 2nd quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after acquiring an additional 264,555 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in IQVIA by 6.6% in the 2nd quarter. Canada Pension Plan Investment Board now owns 3,403,488 shares of the medical research company’s stock valued at $719,634,000 after acquiring an additional 211,653 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. lifted its stake in IQVIA by 285.1% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 268,552 shares of the medical research company’s stock worth $56,783,000 after purchasing an additional 198,808 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.